Abstract:Exosomes are secreted extracellular vesicles carrying diverse molecular cargos, which can modulate recipient cell behaviour. They are thought to derive from intraluminal vesicles formed in late endosomal multivesicular bodies (
MVB
s). An alternate exosome formation mechanism, which is conserved from fly to human, is described here, with exosomes carrying unique cargos, including the
GTP
ase Rab11, generated in Rab11‐positive recycling endosomal
MVB
… Show more
“…Tumour-derived EVs support broad oncogenic processes such as angiogenesis [10] , immune modulation [ 11 , 12 ], and metastasis [13] , [14] , [15] , [16] , [17] . Compared to non-malignant cells, cancer cells have been found to increase the amount of EVs produced [18] , [19] , [20] , shift the subtype of EVs that they secrete [21] , and/or alter the cargo molecules that are selected for expulsion [ 2 , 22 , 23 ]. Of note, education by tumor cells can also affect the secretion rate and the content of EVs derived from platelets [24] , as well as noncancer cells in the TME [8] , but in this review we chose to focus on EV secretion from cancer cells only.…”
Section: Oncogenes and Tumor Suppressors Governing Ev Secretionmentioning
confidence: 99%
“…Besides this tumor intrinsic link between metabolism and EV secretion, extrinsic changes in cancer cell metabolism can also influence the production of cancer EVs. A recent publication reported that the depletion of glutamine from the TME causes a shift in the subtype of cancer EVs that are released; switching from late-endosomal CD63-positive exosomes towards RAB11a-positive exosomes that originate from recycling endosomes and promote tumor vascularization [21] .…”
Section: Tumor Characteristics Linked To Ev Upregulationmentioning
confidence: 99%
“…In hepatic stellate cells mTORC1 signaling enhances EV secretion [79] , while in mouse embryonic fibroblasts mTORC1 signaling inhibits Rab27a-dependent exosome secretion [80] . In various cancer cell lines, mTORC1 inhibition with rapamycin or via glutamine deprivation induce the secretion of protumorigenic RAB11-positive exosomes [21] .…”
Section: Tumor Characteristics Linked To Ev Upregulationmentioning
The discovery that cancer cells discharge vast quantities of extracellular vesicles (EVs), underscored the explosion of the EV field. A large body of evidence now supports their onco-functionality in an array of contexts; stromal crosstalk, immune evasion, metastatic site priming, and drug resistance - justifying therapeutic intervention. The current bottleneck is a lack of clear understanding of why and how EV biogenesis ramps up in cancer cells, and hence where exactly avenues for intervention may reside. We know that EVs also play an array of physiological roles, therefore effective anticancer inhibition requires a target distinct enough from physiology to achieve efficacy. Taking the perspective that EV upregulation may be a consequence of the tumor landscape, we examine classic mutational events and tumor characteristics for EV regulators. All the while, aiming to illuminate topics worth further research in therapeutic development.
“…Tumour-derived EVs support broad oncogenic processes such as angiogenesis [10] , immune modulation [ 11 , 12 ], and metastasis [13] , [14] , [15] , [16] , [17] . Compared to non-malignant cells, cancer cells have been found to increase the amount of EVs produced [18] , [19] , [20] , shift the subtype of EVs that they secrete [21] , and/or alter the cargo molecules that are selected for expulsion [ 2 , 22 , 23 ]. Of note, education by tumor cells can also affect the secretion rate and the content of EVs derived from platelets [24] , as well as noncancer cells in the TME [8] , but in this review we chose to focus on EV secretion from cancer cells only.…”
Section: Oncogenes and Tumor Suppressors Governing Ev Secretionmentioning
confidence: 99%
“…Besides this tumor intrinsic link between metabolism and EV secretion, extrinsic changes in cancer cell metabolism can also influence the production of cancer EVs. A recent publication reported that the depletion of glutamine from the TME causes a shift in the subtype of cancer EVs that are released; switching from late-endosomal CD63-positive exosomes towards RAB11a-positive exosomes that originate from recycling endosomes and promote tumor vascularization [21] .…”
Section: Tumor Characteristics Linked To Ev Upregulationmentioning
confidence: 99%
“…In hepatic stellate cells mTORC1 signaling enhances EV secretion [79] , while in mouse embryonic fibroblasts mTORC1 signaling inhibits Rab27a-dependent exosome secretion [80] . In various cancer cell lines, mTORC1 inhibition with rapamycin or via glutamine deprivation induce the secretion of protumorigenic RAB11-positive exosomes [21] .…”
Section: Tumor Characteristics Linked To Ev Upregulationmentioning
The discovery that cancer cells discharge vast quantities of extracellular vesicles (EVs), underscored the explosion of the EV field. A large body of evidence now supports their onco-functionality in an array of contexts; stromal crosstalk, immune evasion, metastatic site priming, and drug resistance - justifying therapeutic intervention. The current bottleneck is a lack of clear understanding of why and how EV biogenesis ramps up in cancer cells, and hence where exactly avenues for intervention may reside. We know that EVs also play an array of physiological roles, therefore effective anticancer inhibition requires a target distinct enough from physiology to achieve efficacy. Taking the perspective that EV upregulation may be a consequence of the tumor landscape, we examine classic mutational events and tumor characteristics for EV regulators. All the while, aiming to illuminate topics worth further research in therapeutic development.
“…Very recently, using Drosophila model and human cell lines, Fan et al (2020) have found that glutamine depletion induces secretion of exosomes carrying exclusive cargos created in Rab11−positive recycling endosomal MVBs. Interestingly, the release of exosomes from glutamine depleted HCT116 cells stimulate angiogenesis and enhances tumor cell proliferation.…”
Section: Autophagy and Exosomes Relationship In Cancermentioning
Autophagy is an intracellular degradation process involved in the removal of proteins and damaged organelles by the formation of a double-membrane vesicle named autophagosome and degraded through fusion with lysosomes. An intricate relationship between autophagy and the endosomal and exosomal pathways can occur at different stages with important implications for normal physiology and human diseases. Recent researches have revealed that extracellular vesicles (EVs), such as exosomes, could have a cytoprotective role by inducing intracellular autophagy; on the other hand, autophagy plays a crucial role in the biogenesis and degradation of exosomes. Although the importance of these processes in cancer is well established, their interplay in tumor is only beginning to be documented. In some tumor contexts (1) autophagy and exosome-mediated release are coordinately activated, sharing the molecular machinery and regulatory mechanisms; (2) cancer cell-released exosomes impact on autophagy in recipient cells through mechanisms yet to be determined; (3) exosome-autophagy relationship could affect drug resistance and tumor microenvironment (TME). In this review, we survey emerging discoveries relevant to the exosomes and autophagy crosstalk in the context of cancer initiation, progression and recurrence. Consequently, we discuss clinical implications by targeting autophagy-exosomal pathway interaction and how this could lay a basis for the purpose of novel cancer therapeutics.
“…A recent article by Fan et al () clearly illustrates the power of such cell biology approaches. In this work, the authors now demonstrate an additional complexity of EVs formed intracellularly in endosomes, by showing that exosomes can contain the usual late endosomal compartments such as the tetraspanin CD63 and the Rab7 intracellular trafficking GTPase, but also molecular actors of earlier endosomal compartment such as Rab11a that decorates recycling endosomes.…”
Section: Potential Switch Of Exosome Biogenesis Pathways During Glutamentioning
Extracellular vesicles mediate transfer of diverse molecular content to target cells in order to induce phenotypic changes, which has put them under the spotlight as likely major players in cell‐to‐cell communication. However, extracellular vesicle heterogeneity in terms of intracellular origin has only recently been recognized as a potential determinant of their activity. Recent work by Fan et al (2020) illustrates how lack of external resources that affect cellular homeostasis and signaling can also modulate EV biogenesis, by inducing the production of a novel subpopulation of exosomes enriched in Rab11a with context‐dependent roles in Drosophila gland physiology and cancer cell aggressiveness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.